Analytical Validation of the Mate Health At-Home Semen Collection and Transport System
A 222-specimen transport stability study conducted by an independent CLIA-certified, CAP-accredited high-complexity andrology laboratory
Mate Health's at-home semen collection and transport system was analytically validated in a 222-specimen study conducted by an independent CLIA-certified, CAP-accredited high-complexity andrology laboratory, demonstrating strong agreement across 10 semen parameters for up to 34 hours under controlled cooled transport conditions.
Abstract
Background
Male factor infertility contributes to approximately 40–50% of all cases of couple infertility, yet access to male reproductive evaluation remains constrained by structural barriers including clinic availability, scheduling demands, and the logistical requirements of in-clinic semen collection. Expanding access through standardized at-home collection workflows represents a meaningful opportunity to support earlier identification of male reproductive concerns.
Semen analysis is particularly vulnerable to pre-analytical variability. Parameters including motility, progressive motility, and concentration may decline following collection when specimens are exposed to uncontrolled temperatures or prolonged transport intervals without adequate preservation. In decentralized testing workflows, pre-analytical variability represents the primary risk to analytical fidelity, laboratory reproducibility, and the interpretability of results within physician-guided reproductive evaluation.
The Mate Health transportation system was developed as a temperature-controlled semen transport and preservation platform designed to reduce pre-analytical variability and support extended specimen stability during shipment under defined environmental conditions.
Clinical and Operational Context
Access barriers, geographic limitations, scheduling delays, and clinic-based collection requirements may contribute to delayed or foregone male reproductive evaluation. Transport preservation systems are intended to support analytical specimen stability during decentralized collection workflows while maintaining integration with physician-guided fertility evaluation pathways.
Within this context, the analytical integrity of transported specimens, not simply their physical delivery, determines the interpretive utility of at-home collection systems. Transport validation studies evaluate whether defined cooled transport conditions preserve sufficient analytical alignment with baseline measurements to support interpretability within standard reproductive laboratory workflows.
Study Overview
Table 1. Study design summary
| Study type | Independent analytical transport validation study. Conducted by an independent CLIA-certified, CAP-accredited high-complexity andrology laboratory; sponsored and authorized for publication by Mate Health |
| Sample size | 222 live semen samples |
| Comparison | T0 (baseline, immediately post-collection) vs. T24–34 (delayed transport measurements obtained between 24 and 34 hours post-collection under controlled cooled conditions) |
| Parameters | 10 parameters: concentration (M/ml), motility (%), progressive motility (%), MSC (M/ml), PMSC (M/ml), morphology (%), sperm count (M/ejac.), motile sperm (M/ejac.), progressive sperm (M/ejac.), morphologically normal sperm (M/ejac.) |
| Endpoints | Passing–Bablok regression (slope, R²); PPA; NPA |
| Acceptance thresholds | R² > 0.80; PPA > 80%; NPA > 80% |
| PPA/NPA classification | WHO sixth edition (2021) lower reference limits used to classify results as below-reference or within-reference at T0 and T24–34 |
| Transport duration | Up to 34 hours |
| Transport temperature | Maintained below 15°C throughout |
| Stress testing | Ambient temperatures up to 45°C |
| Preservative | Purpose-formulated for 2°C–15°C; supplied in pre-measured 5ml vials |
Methods
Sample collection and transport
222 live semen samples were collected using the Mate Health at-home collection system and analyzed by an independent CLIA-certified, CAP-accredited high-complexity andrology laboratory at two timepoints: T0, obtained immediately following collection, and T24–34, following extended cooled transport. Specimens were maintained throughout the transport interval in a purpose-formulated preservative designed for 2°C–15°C transport conditions. The transport system incorporates cooling components, foil insulation, and unique specimen labeling to support traceability and temperature control.
Analytical endpoints
Analytical agreement and preservation stability between T0 and T24–34 were evaluated using three endpoints. Passing–Bablok regression assessed proportional and systematic bias between baseline and delayed transport measurements; slopes near 1.0 with minimal intercept support strong analytical agreement between timepoints. Positive Predictive Agreement (PPA) assessed the proportion of specimens classified as below-reference at T0 that were correctly classified as below-reference at T24–34. Negative Predictive Agreement (NPA) assessed the proportion of specimens classified as within-reference at T0 that were correctly classified as within-reference at T24–34. Classification at both timepoints was based on WHO sixth edition (2021) lower reference limits. Predefined acceptance thresholds were R² > 0.80, PPA > 80%, and NPA > 80%.
Temperature sustainability
Transport temperature performance was independently evaluated under standard ambient conditions (~24°C) and under environmental stress conditions up to 45°C, representative of adverse real-world shipment environments including vehicle interiors and uncontrolled loading dock exposures.
Results
Temperature sustainability
Table 2. Temperature sustainability results
| Test condition | Ambient temperature | Duration | Result |
|---|---|---|---|
| Standard transport simulation | ~24°C | > 30 hours | Internal temp maintained below 15°C |
| Environmental stress testing | Up to 45°C | Extended | Sustained cooling performance confirmed |
Analytical agreement: all 10 parameters
Across all 10 evaluated semen parameters, transported specimen measurements demonstrated strong analytical agreement and preservation stability with baseline measurements. All predefined acceptance thresholds were met or exceeded.
Table 3. Passing–Bablok regression, PPA, and NPA: T0 vs. T24–34 (n = 222)
| Parameter | Unit | Passing–Bablok Regression | PPA, % | NPA, % | |
|---|---|---|---|---|---|
| Slope | R² | Threshold > 80% |
Threshold > 80% |
||
| Concentration | M/ml | 0.99 | 0.97 | 100.0 | 98.1 |
| Motility | % | 0.98 | 0.94 | 100.0 | 90.3 |
| Progressive Motility | % | 0.91 | 0.92 | 100.0 | 91.7 |
| Motile Sperm Conc. (MSC) | M/ml | 1.10 | 0.95 | 100.0 | 100.0 |
| Prog. Motile Sperm Conc. (PMSC) | M/ml | 1.05 | 0.94 | 100.0 | 97.2 |
| Morphology | % | 0.96 | 0.90 | 100.0 | 88.9 |
| Sperm Count | M/ejac. | 0.97 | 0.98 | 100.0 | 100.0 |
| Motile Sperm | M/ejac. | 1.03 | 0.96 | 90.9 | 100.0 |
| Progressive Sperm | M/ejac. | 1.00 | 0.95 | 100.0 | 99.5 |
| Morphologically Normal Sperm | M/ejac. | 0.89 | 0.93 | 100.0 | 96.6 |
Predefined acceptance thresholds: R² > 0.80; PPA > 80%; NPA > 80%. All 10 parameters exceeded all thresholds. Slopes near 1.0 indicate minimal systematic analytical bias introduced during transport under validated conditions. PPA and NPA calculated using WHO sixth edition (2021) lower reference limits. MSC = Motile Sperm Concentration; PMSC = Progressive Motile Sperm Concentration; M/ejac. = million per ejaculate. Full regression outputs including confidence intervals are available upon request.
Discussion
Transport validation studies evaluate whether delayed transport conditions preserve sufficient analytical alignment with baseline measurements for interpretability within standard laboratory workflows. The primary question is not whether some sperm activity declines during transport, as some decline is expected and documented, but whether that decline is systematic, predictable, and analytically manageable within defined transport conditions.
Passing–Bablok regression slopes of 0.89–1.10 across all 10 parameters indicate that T24–34 measurements remain proportionally aligned with T0. No parameter demonstrated systematic over- or under-estimation that would alter specimen classification at the population level. The R² range of 0.90–0.98 confirms strong linear analytical agreement throughout, exceeding the predefined 0.80 threshold across all parameters.
PPA of 100% on 9 of 10 parameters is a particularly relevant finding: specimens classified as below-reference at T0 were correctly classified as below-reference at T24–34 across the large majority of parameters. This supports the interpretability of delayed transport results within physician-guided reproductive evaluation pathways, while recognizing that transport validation does not constitute diagnostic validation or reproductive outcome prediction.
Temperature sustainability under 45°C ambient stress extends the practical utility of the system to adverse real-world shipment environments that may challenge standard transport configurations. Maintaining temperatures below 15°C is especially important for motility and progressive motility preservation, the parameters most sensitive to pre-analytical thermal exposure.
Conclusion
The Mate Health at-home semen collection and transport system demonstrated strong analytical agreement between baseline and delayed semen analysis measurements across 10 evaluated parameters for up to 34 hours under controlled cooled transport conditions. Passing–Bablok slopes near 1.0 and R² values of 0.90–0.98 indicate minimal systematic analytical bias after transport. PPA and NPA exceeded predefined acceptance thresholds across all parameters, supporting interpretability of delayed transport results when standardized collection and shipping protocols are followed.
These findings support use of the Mate Health system as part of physician-guided male reproductive evaluation when standardized collection, preservation, and transport conditions are maintained. Results should be interpreted by a qualified clinician in the context of reproductive history, partner evaluation, and other relevant clinical findings. This study does not establish diagnostic equivalence, fertility prognosis, or reproductive outcome prediction.
Scope and Limitations
Scientific Review
This report was reviewed by Nicholas Farber, MD, a board-certified urologist with clinical expertise in male reproductive health, male infertility, and post-vasectomy care.